With the results of the current study combined with those above, it should be highlighted that de-escalation of adjuvant TKI therapy might be feasible for completely resected EGFR-mutated NSCLC after adjuvant chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.